Literature DB >> 15878862

Fine tuning of the specificity of an anti-progesterone antibody by first and second sphere residue engineering.

Olivier Dubreuil1, Marc Bossus, Marc Graille, Maëlle Bilous, Alexandra Savatier, Michel Jolivet, André Ménez, Enrico Stura, Frédéric Ducancel.   

Abstract

The specificity of anti-progesterone P15G12C12G11 antibody was improved by combination of in vitro scanning saturation mutagenesis and error-prone PCR. The most evolved mutant is able to discriminate against 5beta- or 5alpha-dihydroprogesterone, 23 and 15 times better than the starting antibody, while maintaining the affinity for progesterone that remains in the picomolar range. The high level of homology with anti-progesterone monoclonal antibody DB3 allowed the construction of three-dimensional models of P15G12C12G11 based on the structures of DB3 in complex with various steroids. These models together with binding data, derived from site-directed mutagenesis, were used to build a phage library in which five first sphere positions in complementarity-determining regions 2H and 3L were varied. Variants selected by an initial screening in competition against a large excess of 5beta- or 5alpha-dihydroprogesterone were characterized by a convergent amino acid signature different from that of the wild-type antibody and had lower cross-reactivity. Binding properties of this first set of mutants were further improved by the addition of second sphere mutations selected independently from an error-prone library. The three-dimensional models of the best variant show changes in the antigen binding site that explain well the increase in selectivity. The improvements are partly linked to a change in the canonical class of the light chain third hypervariable loop.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15878862     DOI: 10.1074/jbc.M500048200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  10 in total

Review 1.  Molecular engineering of antibodies for therapeutic and diagnostic purposes.

Authors:  Frédéric Ducancel; Bruno H Muller
Journal:  MAbs       Date:  2012-07-01       Impact factor: 5.857

2.  A reduced amino acid alphabet for understanding and designing protein adaptation to mutation.

Authors:  C Etchebest; C Benros; A Bornot; A-C Camproux; A G de Brevern
Journal:  Eur Biophys J       Date:  2007-06-13       Impact factor: 1.733

Review 3.  Engineering the variable region of therapeutic IgG antibodies.

Authors:  Tomoyuki Igawa; Hiroyuki Tsunoda; Taichi Kuramochi; Zenjiro Sampei; Shinya Ishii; Kunihiro Hattori
Journal:  MAbs       Date:  2011-05-01       Impact factor: 5.857

Review 4.  The development of immunoconjugates for targeted cancer therapy.

Authors:  Brandon G Smaglo; Dalal Aldeghaither; Louis M Weiner
Journal:  Nat Rev Clin Oncol       Date:  2014-09-30       Impact factor: 66.675

5.  Tuning the specificity of a Two-in-One Fab against three angiogenic antigens by fully utilizing the information of deep mutational scanning.

Authors:  Patrick Koenig; Sarah Sanowar; Chingwei V Lee; Germaine Fuh
Journal:  MAbs       Date:  2017-06-06       Impact factor: 5.857

6.  Exploiting cross-reactivity to neutralize two different scorpion venoms with one single chain antibody fragment.

Authors:  Lidia Riaño-Umbarila; Gabriel Contreras-Ferrat; Timoteo Olamendi-Portugal; Citlalli Morelos-Juárez; Gerardo Corzo; Lourival D Possani; Baltazar Becerril
Journal:  J Biol Chem       Date:  2010-12-14       Impact factor: 5.157

7.  Creation of recombinant antigen-binding molecules derived from hybridomas secreting specific antibodies.

Authors:  Conor Fields; David O'Connell; Sujing Xiao; Gil U Lee; Philippe Billiald; Julien Muzard
Journal:  Nat Protoc       Date:  2013-05-16       Impact factor: 13.491

8.  Closely related antibody receptors exploit fundamentally different strategies for steroid recognition.

Authors:  Petra Verdino; Caroline Aldag; Donald Hilvert; Ian A Wilson
Journal:  Proc Natl Acad Sci U S A       Date:  2008-08-08       Impact factor: 11.205

9.  The clinical potential of circulating tumor cells; the need to incorporate a modern "immunological cocktail" in the assay.

Authors:  Jonathan W Uhr
Journal:  Cancers (Basel)       Date:  2013-12-13       Impact factor: 6.639

Review 10.  Lateral Flow Assays in Infectious Disease Diagnosis.

Authors:  Hans R Boehringer; Brendan J O'Farrell
Journal:  Clin Chem       Date:  2021-12-30       Impact factor: 12.167

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.